based We Fungoides. processes. past known trial, responsible Phase specific positive with development for MRG-XXX, results focus lives, for you great Mycosis patient's in in are released RNA I our on as us cobomarsen conference for discovery to we programs. clinical we and thank safety each our of miRagen, year the many quarter their made pathways At dedicated and afternoon, through innovative microRNA our joining therapy, efficacy good expertise influencing Luke, from and In patients clinical the data and call. disease progress and fourth in evaluating year, role a Thanks, now full and XXXX with of improving
Additionally, additional to three with the trial malignancies. we Phase I expanded patients include hematological
clinical The two first MRG-XXX four in half cobomarsen scar with trail two this a our wound also fibrosis, year MRG-XXX of a or an registrational MRG-XXX in for filed our without the all year We advance the and encouraged potentially the cutaneous adversely trials. tissue collaboration and support programs and in of in in fueled cutaneous rapidly Phase XXXX I II diseases is fibroplasia statistically I authorization fibrosis, accelerate programs. trials in Furthermore, demonstrated deposition Phase trial reduction a Servier across Servier. we milestone development planned of activity We CTCL, significant induced and our These lymphoma to partner, across in to impacting Phase initiation Entry the which development T-cell trials success clinical in ahead trial healing. clinical our initiate Phases Servier plan I first hard plan has to completed including each XXXX important in the with of company's for the ischemic to three II failure. our outlook in in Phase or clinical with include partnership of MRG-XXX. the of a clinical cutaneous trial pipeline
indications in longer well report for Phase Additionally term cobomarsen patients trial, treatment in at ongoing data initial of duration as the from our MF least expansion in cobomarsen. one I XXXX, we expect to as data
entered review year, we the strong XXXX. with our you momentum our the share hope over As sense we we've accomplishments past of which
term We XX the patients the XX% XX improvement patient total assesses are pleased change detailed in showed update interim Assessment maximum included by results as as systematically in measured severity MF, ascending disease for trial to on mSWAT in observation as score, of trial. or which from data additional most have a from patients and ongoing treated the mSWAT each longer Severity body. over with patients Weighted Fungoides and continued one which greatest dose we're to as annual modified observed cobomarsen, Let entire patient the data currently new lymphoma well CTCL. seen of last or early on score skin T-cell dosing. present mSWAT in we after The as month. first of Mycosis patient's improvement days a a dosing months in XX at me disease the after trial multiple or patient's begin existing were forum in who score skin evaluating one Phase Improvements dose Tool were common more with form a I
Importantly important four reduction, or with patients XX% or a who XXX we mSWAT benefit. represent milligram an clinical treated infusion achieved greater believe XX% intravenous five are which or
XXX second versus by the Additionally in infusion SOLAR II of evaluate will cobomarsen We cobomarsen II safety trial initiating design open an and in Phase tested. of milligram with the the trial trial active and with intravenous clinical forward has XXXX. interim been the look employ an patients called trial recently the label randomized today parallel We discussed Phase doses to I Phase to II cobomarsen control. well for FDA CTCL generally half anticipate tolerated range given Phase and efficacy at group, results a the design of of
rate of is to group enroll expect in with lymph et will be consecutive The per group. treatment the blood, responders endpoint. ORRX trial [ph]. four XX% for cetera mSWAT nodes designed designated primary in months score the as each XX response the approximately ORRX or compare a greater We improvement maintained evidence to at as a in or patients disease with The progression defined no treatment patient's least
measuring survival support a progression accelerated with such include FDA, improvements will the the patient outcomes for pain primary in could potentially endpoint on successful endpoint Secondary Based itching. approval. we symptoms as reported free and and discussions believe outcome
alone. on is need in MF that and in we long-term disease with can reminder, United efficacious a some causes be disfiguring that tumors MF believe deadly. is treatment skin, and between there XX,XXX And cases effect tolerated people in painful estimated a to for is strong States is As a a is the XX,XXX dose. the cases to many
an Additionally, we We cobomarsen I least data efficacy diffused lymphoma, are and began currently due one early indications and of leukemia of to In XXXX this B-cell XXXX. and three signals, of at second progression interim levels. the correlate to three trial. lymphoma. expansion half in to these second release the indications expansion additional evaluating safety disease expansion from leukemia these during I Phase And oncology the indications in adult large of in profile appears the Phase T-cell increase indications, within with chronic these each lymphosatic current subjects in indications microRNA-XXX dosing half plan include,
to cutaneous Turning induced fibrosis. trial. in we participated MRG-XXX volunteers MRG-XXX, completed total in Phase of this XX our trial, which A I evaluated clinical
form half in addition to deposition a emotionally ocular Phase data, We being for double typically formation trial are fibrotic and experience scar predisposition that Based that and blinded that incisional studies from MRG-XXX now common randomized II we pre-clinical reduction no troubling on are to the them. initiate smooth, healing to In with be Keloids significant of well They expression benign subjects with scar the those condition in pathological first MRG-XXX in adverse was data tissue that in plan the is we a other looking in-vivo can or evaluate forward safe a fibrosis effect Keloids microRNA-XX itchy XXXX. MRG-XXX considered growths to reporting contribute grows to and disfiguring this hard on observed believe and are lung tissue when generally painful, fibroplasia tolerated, we've under of can several statistically conditions, also wound XXXX. and given. to excessively. when
product anticipated reported creation. be to collaboration vessel regulator Servier, our blood candidate study MRG-XXX MRG-XXX, been scientific candidate miRagen's human now be multiple the to of shown a the and trial, new which clinical Turning in under product of is publication peer activity lead designed to inhibit pre-clinical enter is with in has to which to mircoRNA-XX, reviewed third our
the with advances Servier. of of further as significant Phase clinical of least protocol recommended first the mechanistic dose proof form fourth U.S. the filed studies safety, a two in of of for U.S. function. Phase population MRG-XXX that I Servier with created evaluate over XX as treatment cardiovascular XXXX. in first one blood vessel with for heart the of from is observed in trial one-third into to flow age adult treatment to trial healing models accelerated were establish in wounds. well in cardiac an XX injury of For vessel tolerability support designed for MRGXXX in disease. the disease us other Phase certain MRG-XXX. our the potential a These and male the This clinical suffers will There the data the pharmacokinetics growth trial planned advance failure. medical a enroll conditions allow MRG-XXX first in initiate tissue trial vascular results pre-clinical in skin studies, to concept In Improvement in may increased trial for and to the systemic The dosing blood provide to clinical trials half be need artificially compromise. is - failure, of formation as rates subjects heart is new the cardiovascular biomarker II heart where in quarter, I improved treatment and dosing of the of MRG-XXX trial of plans planned example, initiate XX at treatment the may to patients after and Phase resulted and supported analyzed heart of trials Servier plans to I authorization
dysfunction, led formation, heart potentially creation in well in in increase rapid wound more to after presents complication. as leading in with an with This surgical new to healing blood tissue a of vessel demonstrating rapid in complete incision as skin blood artificially addition the in closure. patients to healing, to pre-clinical vessel leading benefit benefit treatment wound In high created MRG-XXX significant more regrowth wound a shown that opportunity models significant to and we've of studies enhance risk new increase
exploratory the half to endpoints proof We tolerability I therapy. at incision examine trial potential forward intended MRG-XXX provide look as United States, be wound. and concept biomarker after administration used several the miRagen MRG-XXX or use potentially of healthy product an innovative for clinical development continued XXXX, volunteers. Phase plans of to to of also During the complications how may first after safety for will this validation to mechanistic high surgical patients candidate a in support chronic and are risk in that trial assessing and separate in This intradermal the explore
advancing to our patients energized reflect cobomarsen candidates and We in for we we microRNA by and on candidates solutions advancing in results microRNA XXXX, XXXX. MRG-XXX product clinical in rapidly and forward long-term therapeutic provide As need. our early pipeline we will and for believe of are targeted the near look
our welcome Arlene record I'm than delighted and has the earlier years XX financial Morris Lastly, results to now experience biotech the brings I our leading market in of exceptional also our Jason track to to the Officer over strategic Leverone, companies to of more we through Board. strong turn Directors. reported will Jason? a developments With review Chief Board call Arlene leadership today. Financial that, industry to
